Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

de Claro, R. Angelo, McGinn, Karen M., Verdun, Nicole, Lee, Shwu-Luan, Chiu, Haw-Jyh, Saber, Haleh, Brower, Margaret E., Chang, C.J. George, Pfuma, Elimika, Habtemariam, Bahru, Bullock, Julie, Wang, Yun, Nie, Lei, Chen, Xiao-Hong, Lu, Donghao (Robert), Al-Hakim, Ali, Kane, Robert C., Kaminskas, Edvardas, Justice, Robert, Farrell, Ann T., Pazdur, Richard · 2015 · Clinical Cancer Research

Abstract

On November 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On February 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval. Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clinical trials in patients with prior treatment. In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, respectively, for an ORR of 65.8% [95% confidence interval (CI), 56.2%–74.5%]. The median DOR was 17.5 months (95% CI, 15.8–not reached). In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%–72.4%), and the DOR ranged from 5.6 to 24.2 months. The most common adverse reactions (≥30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea. Clin Cancer Res; 21(16); 3586–90. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2225

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 171

Metadata

Authors
de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., Bullock, J., Wang, Y., Nie, L., Chen, X.-H., Lu, D. (., Al-Hakim, A., Kane, R. C., Kaminskas, E., Justice, R., Farrell, A. T., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2015-08-13
Volume
21
Issue
16
Pages
3586-3590
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1908764360
Cited by
171
References
4
FWCI
7.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2225
The paper
de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., Bullock, J., Wang, Y., Nie, L., Chen, X.-H., Lu, D. (., Al-Hakim, A., Kane, R. C., Kaminskas, E., Justice, R., . . . Pazdur, R. (2015). FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.